Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

Area of Science:

• Diabetes Technology
• Endocrinology
• Biomedical Engineering

Background:

• Diabetes management has seen significant technological advancements over the last decade.
• Continuous Glucose Monitors (CGMs) and insulin-delivery systems have evolved substantially.
• Hybrid closed-loop systems represent a major step in automated diabetes care.

Purpose of the Study:

• To review recent advancements in diabetes technology, focusing on Continuous Glucose Monitors (CGMs).
• To highlight improvements in CGM accuracy, usability, and emerging technologies.
• To project the future impact of CGMs on daily diabetes care.

Main Methods:

• Review of current Continuous Glucose Monitor (CGM) technologies and their performance metrics (e.g., MARD).
• Analysis of new features including calibration requirements, wear duration, and insertion sites.
• Discussion of emerging CGM devices and their potential integration with automated insulin delivery (AID) systems.

Main Results:

• Modern CGMs exhibit Mean Absolute Relative Differences (MARD) below 10%, a significant improvement from over 20% a decade ago.
• Many new CGMs offer calibration-free operation, extended wear times (10-14 days), and features like predictive alarms.
• Newer devices like Eversense-3 and Libre 3 show advancements, though interoperability with AID systems remains a challenge for some.

Conclusions:

• Continuous Glucose Monitors (CGMs) have achieved remarkable accuracy and user convenience.
• Ongoing innovation in CGM technology, including improved sensors and predictive features, is rapidly enhancing diabetes management.
• A substantial increase in CGM adoption for daily diabetes care is anticipated in the coming decade.